Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

ÖZKAYA, Hande; Sahin, Serdar; Korkmaz, Ozge; DURCAN, Emre; Sahin, Humeyra; ÇELİK, Emir; POYRAZ, BURÇ; KADIOĞLU, Pınar

doi:10.1016/j.ghir.2020.101356

Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

ÖZKAYA H. M., Sahin S., Korkmaz O. P., DURCAN E., Sahin H. R., ÇELİK E., ...Daha Fazla

GROWTH HORMONE & IGF RESEARCH, cilt.55, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 55
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.ghir.2020.101356
Dergi Adı: GROWTH HORMONE & IGF RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
Anahtar Kelimeler: Acromegaly, Dopamine agonist, Impulse control disorder, Prevalence, NONFUNCTIONING PITUITARY-ADENOMAS, COMPULSIVE BEHAVIORS, PARKINSONS-DISEASE, SHORT-FORM, AGE, HYPERPROLACTINEMIA, ASSOCIATION, PERSONALITY, CABERGOLINE, THERAPY
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).